LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

105.39 +1.78 (+1.72%)

Streaming Delayed Price Updated: 2:55 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

LeMaitre (LMAT) Stock Trades Up, Here Is Why

February 26, 2026

Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 16.8% in the morning session after the company reported strong fourth-quarter 2025 results that surpassed Wall Street's...

Via StockStory

LeMaitre (NASDAQ:LMAT) Surprises With Q4 CY2025 Sales, Stock Soars

February 25, 2026

Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15.7% year on year to $64.45 million. Guidance for next quarter’s revenue was...

Via StockStory

LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect

February 23, 2026

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

1 of Wall Street’s Favorite Stock on Our Buy List and 2 We Find Risky

February 08, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

3 Small-Cap Stocks We Keep Off Our Radar

February 04, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

1 High-Flying Stock for Long-Term Investors and 2 That Underwhelm

January 20, 2026

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...

Via StockStory

1 Cash-Producing Stock with Solid Fundamentals and 2 We Ignore

January 11, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

3 Profitable Stocks That Concern Us

December 28, 2025

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

Reflecting On Surgical Equipment & Consumables - Specialty Stocks’ Q3 Earnings: LeMaitre (NASDAQ:LMAT)

December 24, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - specialty stocks fared in...

Via StockStory

Topics Artificial Intelligence Economy

LeMaitre Vascular Inc (NASDAQ:LMAT) Embodies Quality Investing Principles ↗

December 23, 2025

LeMaitre Vascular exemplifies quality investing with strong revenue growth, exceptional capital returns, and a debt-light balance sheet.

Via Chartmill

1 Small-Cap Stock to Target This Week and 2 That Underwhelm

December 17, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

1 Cash-Heavy Stock with Impressive Fundamentals and 2 We Question

December 09, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

1 Reason LMAT is Risky and 1 Stock to Buy Instead

November 27, 2025

LeMaitre currently trades at $83.37 per share and has shown little upside over the past six months, posting a middling return of 2.9%. The stock also fell short of the S&P 500’s 15.6% gain during that...

Via StockStory

Topics Stocks Supply Chain

LeMaitre (LMAT) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

LeMaitre (LMAT) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

3 Healthcare Stocks We Steer Clear Of

November 24, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Via StockStory

Topics Stocks

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Via StockStory

Topics Economy

LeMaitre Vascular Inc (NASDAQ:LMAT) Stands Out as a Quality Investment Using the Caviar Cruise Screen ↗

November 14, 2025

LeMaitre Vascular (LMAT) is a high-quality medical device company with strong revenue & EBIT growth, a 32.83% ROIC, and a solid financial profile.

Via Chartmill

3 Russell 2000 Stocks Walking a Fine Line

November 13, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

5 Must-Read Analyst Questions From LeMaitre’s Q3 Earnings Call

November 13, 2025

LeMaitre’s third quarter results drew a negative market reaction as revenue trailed Wall Street expectations, despite solid year-over-year growth. Management cited strong performances from the Grafts...

Via StockStory

Topics Earnings

LMAT Q3 Deep Dive: Pricing and Margin Expansion Offset by Cautious Growth Outlook

November 07, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of...

Via StockStory

LeMaitre (NASDAQ:LMAT) Reports Sales Below Analyst Estimates In Q3 Earnings

November 06, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance...

Via StockStory

LeMaitre Earnings: What To Look For From LMAT

November 04, 2025

Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Thursday after the bell. Here’s what investors should know.

Via StockStory

3 Cash-Producing Stocks We Think Twice About

October 31, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

Where LeMaitre Vascular Stands With Analysts ↗

October 15, 2025

Via Benzinga

3 of Wall Street’s Favorite Stocks We Think Twice About

October 14, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: LeMaitre (NASDAQ:LMAT) Shines

October 06, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ:LMAT) and its peers.

Via StockStory

Topics Artificial Intelligence Economy

1 High-Flying Stock with Solid Fundamentals and 2 We Ignore

October 06, 2025

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly...

Via StockStory

Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement

September 30, 2025

New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a...

Via MarketMinute

Topics Government

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Via MarketMinute

Topics Economy Government World Trade

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.